Henry Ginsberg is the Irving Professor of Medicine at the Columbia University Irving Medical Center, New York. From 1994 until 2017, he was the Director of the Irving Center for Clinical Research (1994-2006) which became the Irving Institute for Clinical and Translational Research (2006-2017).  He has been director of an NIH-funded T32 Postdoctoral Training Grant in Arteriosclerosis from 1991 until the present time. His research interests have centered on regulation of the metabolism of apolipoprotein B containing lipoproteins, including very low density lipoproteins, low density lipoproteins, and lipoprotein (a), in cells, mice and humans. More recently he added studies of the regulation of hepatic lipid homeostasis and MAFLD to his research interests.

Dr. Ginsberg has published over 400 peer-reviewed and invited papers. He is a member of the ASCI and AAP, and a Fellow of the AAAS. He has received funding from the NIH for more than 40 years and has collected numerous awards and given named lectureships from the American Heart Association (AHA), the American Diabetes Association (ADA), and the European Atherosclerosis Society (EAS). In 2017, Dr. Ginsberg received an Outstanding Investigator Award from the NIH/NHLBI providing $4 million in direct support over 7 years. 

Dr. Ginsberg has participated in many pharma-funded studies related to lipid disorders and has consulted/advised for all of the major pharma companies on the topic of lipid and lipoprotein metabolism as well as the effects of all classes of lipid-altering medications.  He was the lead investigator for the ACCORD Lipid trial. In addition to his research and training activities, Dr. Ginsberg sees patients with severe and rare lipid disorders including patients with Familial Hypercholesterolemia, Familial Chylomicronia Syndrome, and Multigenic Severe Hypertriglyceridema.